Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00346801 · ClinicalTrials.gov registry record · Phase 1

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

A Phase 1 study of Lung Cancer, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT00346801: Completed Phase 1 study of Lung Cancer, sponsored by M.D. Anderson Cancer Center.

NCT00346801 is a Phase 1 study of Lung Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00346801, a Phase 1 study of Lung Cancer, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Primary Objectives: * To determine the feasibility, activity, and toxicity of a novel regimen using a concurrent irinotecan (CPT-11)/cisplatin and celecoxib combination for patients with unresectable NSCLC. * To determine the maximal tolerance dose of celecoxib in patients with unresectable NSCLC treated with irinotecan/cisplatin and concurrent thoracic radiation therapy. * To correlate the COX-2 expression and other biomarkers with response to the treatment in the tumor from a pretreatment biopsy specimen.

Conditions Studied

Interventions

  • DRUG Cisplatin
  • DRUG Celecoxib
  • DRUG CPT-11
  • RADIATION Concurrent Thoracic Radiation Therapy

Study Locations (1)

Texas

  • UT MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2003-09
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00346801 record still lists

NCT00346801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.

NCT00346801 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00346801 about?

NCT00346801 is a clinical study titled "CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)". Primary Objectives: * To determine the feasibility, activity, and toxicity of a novel regimen using a concurrent irinotecan (CPT-11)/cisplatin and celecoxib combination for patients with unresectable NSCLC. * To determine the maximal tolerance dose of celecoxib in patients with unresectable NSCLC t...

What is the current status of trial NCT00346801?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2003-09.

What conditions does trial NCT00346801 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00346801?

The interventions under investigation include: Cisplatin (DRUG), Celecoxib (DRUG), CPT-11 (DRUG), Concurrent Thoracic Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT00346801?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00346801 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00346801's enrollment target sits among peer trials

20 356th of 409 higher than 46 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00346801, the US trial registry maintained by the National Library of Medicine. NCT00346801 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.